Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659005 | 0.90 | CYP3A4 (0.44) | F10OPRD1CYP3A4ROCK2CHRNA7 | |
| SCHEMBL5660301 | 0.89 | CALCRL (0.49) | F10OPRD1CYP3A4ROCK2CHRNA7 | |
| SCHEMBL5660915 | 0.89 | F10 (0.51) | F10OPRD1CYP3A4ROCK2CALCRL | |
| SCHEMBL5660672 | 0.84 | CYP3A4 (0.62) | OPRD1CYP3A4ROCK2CALCRL | |
| SCHEMBL5659284 | 0.84 | F10 (0.43) | F10OPRD1CYP3A4ROCK2CALCRL | |
| SCHEMBL4587732 | 0.82 | CALCRL (0.59) | OPRD1CYP3A4ROCK2CALCRLDPP4 | |
| SCHEMBL5659896 | 0.82 | CALCRL (0.50) | OPRD1CYP3A4ROCK2CHRNA7CALCRL | |
| SCHEMBL3279461 | 0.80 | OPRK1 (0.47) | OPRD1DPP4SMYD3OPRK1 | |
| SCHEMBL3603298 | 0.80 | FAAH (0.46) | OPRD1CYP3A4ROCK2DPP4CHRM2 | |
| SCHEMBL5661010 | 0.80 | ROCK2 (0.44) | OPRD1CYP3A4ROCK2DPP4SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| US-7205294-B2 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BDKRB1, BDKRB2, CALCRL | F10 709/4885OPRD1 23/4885CYP3A4 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.